⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SPRY News
ARS Pharmaceuticals, Inc. Common Stock
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
globenewswire.com
SPRY
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
globenewswire.com
SPRY
Ambulatory EHR Excellence 2026: Top Vendors Recognized for Breakthrough Innovation and Specialty User Satisfaction in Black Book 2026 Surveys
accessnewswire.com
NTST
ATHA
QRHC
PROV
WVE
MTC
WELL
MED
ORCL
SPRY
PATN
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
globenewswire.com
SPRY
Sperry Expands into Europe with First European Affiliate - Cream Property Advisors
accessnewswire.com
SPRY
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
globenewswire.com
SPRY
Marquis Who's Who Recognizes Ellen Bristol for Expertise in Fundraising
accessnewswire.com
SPRY
DECK
WEY
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
globenewswire.com
SPRY
ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
globenewswire.com
SPRY
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
globenewswire.com
SPRY